Life sciences companies are at a major crossroads: The fruits of the traditional blockbuster model have been consumed, and enterprises realize that the way forward is a targeted approach to diseases. Traditional business and operating models are being reviewed and often replaced by new strategies designed to accommodate the rapidly evolving and globalized marketplace.

Supply chains are already experiencing disruption across industries, catalyzed by on-demand delivery models and cost optimization drives. The ripple effects of these changes are also being felt on life sciences supply chains. The traditional hub-and-spoke model is no longer sufficient to meet the needs of the life sciences industry, as it gradually shifts to a precision medicine model. However, challenges such as the lack of end-to-end visibility, rampant counterfeiting and theft, as well as process inefficiencies, still need to be addressed to make supply chains resilient.

This report recommends our ADAPT framework for life sciences supply chains to adopt and adapt according to business requirements and deliver enhanced value to patients.

Scope

• Geography: global
• Industry: life sciences
• Sources leveraged: expert analyst inputs, Everest Group research, publicly available secondary data sources

Contents

In this research, we analyze the life sciences supply chain market across the following dimensions:

• Current state of life sciences supply chains
• Impact of COVID-19 on life sciences supply chains
• Everest Group ADAPT framework for life sciences supply chains
• Life sciences enterprise supply chain initiatives

Membership(s)

Life Sciences IT Services (ITS)